Company intelligence / Profile preview

Eiffel Biotech

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Eiffel Biotech is a preclinical-stage biotechnology company focused on developing next-generation multi-receptor agonists for the treatment of metabolic diseases, including obesity and type 2 diabetes. The company's approach centers on engineering optimized peptide therapies that target the GLP-1, GIP, and glucagon receptors to achieve enhanced weight loss and metabolic health. Led by a team of experienced industry executives, Eiffel Biotech aims to address the limitations of current incretin therapies through improved potency and tolerability. The company is headquartered in Cambridge, Massachusetts, and is backed by leading life sciences venture capital firms.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Eiffel Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eiffel Biotech.

Explore the full profile